Email Page Print Page

Technology Platform

New advances in drug delivery technologies are allowing many existing products to be administered with improved effectiveness, speed, safety and/or ease of administration. Drug delivery technologies are also facilitating the advancement of many new drugs which might not otherwise be feasible without an effective means of administration.

BioDelivery Sciences utilizes patented and proprietary drug delivery technologies to create products and formulations that meet important patient and healthcare provider needs. Presently, our development efforts are centered on the BioErodible MucoAdhesive (BEMA®) technology.

 

BEMA TechnologyBEMA Technology

The BEMA® drug delivery technology consists of a small, bioerodible polymer film for application to the mucosal membranes (inner lining of cheek). BEMA® films were designed to rapidly deliver a dose of drug across the mucous membranes for time sensitive conditions or to facilitate administration of drugs with poor oral (pill) absorption.

BEMA® films are designed to:

 

  • Adhere to oral mucosa in less than 5 seconds
  • Optimize delivery across the oral mucosa
  • Completely dissolve within 15 to 30 minutes


The first product to be developed and marketed using the BEMA® technology was Onsolis® (fentanyl buccal soluble film). Following the successful development and approval of the first product utilizing the BEMA® technology, we began to apply the same technology to improve the delivery of other therapies, such as buprenorphine and buprenorphine/naloxone. The BEMA® technology may also be developed with other active drugs, particularly in conditions where rapid delivery of drug is important, oral dosing is not optimal, or where intravenous line or injections are unavailable or not practical. BDSI owns the worldwide rights to the BEMA® drug delivery technology.

 

 

Learn More

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA
BEMA Buprenorphine on track for late 2014 or early 2015 NDA filing by partner Endo Pharmaceuticals


BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2014 Financials
BUNAVAILâ„¢ (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3